Overview
I am an Advanced Heart Failure and Transplant Cardiologist, and clinical researcher, here at Duke. My research studies outcomes and interventions in patients with Advanced Heart Failure and with heart transplants. Previously, I completed Internal Medicine Residency, and Cardiovascular Medicine and Advanced Heart Failure clinical fellowships here at Duke. I was also an NIH T-32 grant funded Research Fellow at the DCRI. Previously, I completed medical school at the Icahn School of Medicine at Mount Sinai, and was a research fellow in the NIH Medical Research Scholar's program, where I spent 1 year at the National Heart, Lung, and Blood Institute (NHLBI) performing clinical and translational cardiovascular research.
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2025 - Present
Medicine, Cardiology,
Medicine
Recent Scholarly Works
Lost to Follow-Up in Pragmatic Trials With Remote Follow-Up: Insights From CONNECT-HF and TRANSFORM-HF.
Journal article J Am Heart Assoc · August 4, 2026 BACKGROUND: Pragmatic trials commonly use remote follow-up to reduce participant burden and costs. However, these approaches may increase the risk of lost to follow-up (LTFU). We identified patient- and site-level factors associated with LTFU in 2 large, p ... Full text Link to item CiteOrgan-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience.
Journal article Am J Transplant · August 2026 Cytomegalovirus (CMV) causes significant morbidity in CMV donor seropositive/recipient seronegative (D+R-) solid organ transplant recipients, but organ-specific differences in CMV epidemiology and the utility of laboratory surveillance after prophylaxis (S ... Full text Link to item CiteShort-term heart transplant outcomes with heart organ procurement services.
Journal article J Heart Lung Transplant · July 15, 2026 BACKGROUND: Novel heart procurement and preservation strategies have altered the organ procurement landscape. Heart organ procurement services (HOPS) have emerged as integrated businesses to procure and transport donor organs. While HOPS may provide conven ... Full text Link to item CiteRecent Grants
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy
Clinical TrialCo Investigator · Awarded by Novo Nordisk, Inc. · 2026 - 2029View All Grants
Education
Icahn School of Medicine at Mount Sinai ·
2017
M.D.
Brown University ·
2011
B.A.